Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, Genentech

Premium
CombiMatrix Molecular Diagnostics this week launched its HerScan test for breast cancer. HerScan is an array comparative hybridization-based assay designed to detect amplification of the HER2 gene in early breast cancer. The test also provides clinicians with a complete profile of a patient's tumor genome, CMDX said.
 
The College of American Pathologists and the American Society of Clinical Oncology have recommended that HER2 status be determined in all invasive breast cancers as a prognostic marker for which patients are most likely to benefit from Genentech’s breast cancer drug Herceptin.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.